J Drugs Dermatol. 2021 Nov 1;20(11):1239-1244. doi: 10.36849/jdd.6166.
Actinic keratoses (AK) are lesions with potential to transform into nonmelanoma skin cancers. Numerous methods are available for treatment of AK. Here, we review clinical trial data on the use of photodynamic treatment combined with the sensitizing agent aminolevulinic acid 20% solution (ALA-PDT) for AK management. Although treatment guidelines for AK vary in their specific recommendations, efficacy of ALA-PDT is considered comparable or better relative to other FDA-approved treatments for AK. It is generally well tolerated and has a very acceptable long-term safety profile. ALA-PDT is typically recommended for patients who have multiple AKs and is associated with improved cosmetic outcomes compared with cryotherapy. Patients who undergo treatment with ALA-PDT should receive thorough education regarding the risks and benefits of treatment, the treatment regimen and the importance of adhering to it, how to manage local reactions, and signs and symptoms that warrant further evaluation. J Drugs Dermatol. 2021;20(11):1239-1244. doi:10.36849/JDD.6166.
光化性角化病(AK)是一种有潜在可能转化为非黑素瘤皮肤癌的病变。目前有许多方法可用于 AK 的治疗。本文回顾了光动力疗法联合光敏剂 20%氨基酮戊酸(ALA-PDT)治疗 AK 的临床试验数据。虽然 AK 的治疗指南在具体建议上存在差异,但相对于其他获得 FDA 批准的 AK 治疗方法,ALA-PDT 的疗效被认为相当或更好。它通常具有良好的耐受性,且长期安全性极佳。ALA-PDT 通常推荐用于患有多发性 AK 的患者,与冷冻疗法相比,其可获得更好的美容效果。接受 ALA-PDT 治疗的患者应接受关于治疗风险和益处、治疗方案以及坚持治疗的重要性、如何管理局部反应以及需要进一步评估的迹象和症状的全面教育。J 皮肤病药物杂志。2021;20(11):1239-1244. doi:10.36849/JDD.6166.